Clinical Trial Update: An Exploratory Study of the Effects of a Single Dose of QAX576 (an Interleukin-13 Monoclonal Antibody) on Simulated Hayfever [Phase 2]

View source ↗

Summary

A Phase 2 exploratory trial evaluated a single dose of QAX576, an interleukin-13 monoclonal antibody, for effects on simulated hayfever in allergic rhinitis; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• QAX576

Snippet

Sponsor: Novartis | Conditions: Allergic Rhinitis | Phase 2 | Status: COMPLETED